Oak Ridge Investments LLC Increases Position in Alexion Pharmaceuticals, Inc. (ALXN)

Oak Ridge Investments LLC increased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,181 shares of the biopharmaceutical company’s stock after purchasing an additional 3,556 shares during the period. Oak Ridge Investments LLC’s holdings in Alexion Pharmaceuticals were worth $10,729,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ALXN. BlackRock Inc. increased its position in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after purchasing an additional 17,960,356 shares during the last quarter. Bank of Montreal Can increased its position in Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock worth $173,174,000 after purchasing an additional 1,228,025 shares during the last quarter. Bessemer Group Inc. increased its position in Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock worth $87,772,000 after purchasing an additional 721,367 shares during the last quarter. State Street Corp increased its position in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after purchasing an additional 718,756 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in Alexion Pharmaceuticals in the first quarter worth $65,219,000. Institutional investors own 94.26% of the company’s stock.

Alexion Pharmaceuticals, Inc. (ALXN) traded up 1.13% during mid-day trading on Monday, hitting $142.78. The company had a trading volume of 412,026 shares. The company has a 50-day moving average price of $137.04 and a 200 day moving average price of $124.16. The company has a market capitalization of $31.87 billion, a P/E ratio of 61.92 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same period last year, the business posted $1.13 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

In related news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 2,019,734 shares of company stock valued at $235,606,846 and have sold 17,070 shares valued at $2,416,869. Company insiders own 4.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/09/11/oak-ridge-investments-llc-increases-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several brokerages recently weighed in on ALXN. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 20th. Evercore ISI assumed coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They set an “in-line” rating and a $137.00 price objective for the company. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research note on Wednesday, August 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $168.00 price objective (up from $159.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Five research analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $156.32.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply